BRIEF-SQZ Biotechnologies Receives FDA Fast Track Designation For Its Lead Cell Therapy Candidate For The Treatment Of HPV16+ Tumors
* SQZ BIOTECHNOLOGIES RECEIVES FDA FAST TRACK DESIGNATION FOR ITS LEAD CELL THERAPY CANDIDATE FOR THE TREATMENT OF HPV16+ TUMORS Source text for Eikon: Further company coverage: